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Posterior reversible encephalopathy syndrome (PRES) is a clinical syndrome characterized by vision changes,
altered mental status, and seizures, typically caused by an acute rise in blood pressure. PRES has been re-
ported after hematopoietic stem cell transplantation (HSCT) in association with hypertension from calci-
neurin inhibitors and corticosteroids. The imaging evaluation of PRES after HSCT in children and young adults
has not been well described. We performed a retrospective review of all HSCT recipients presenting to the
intensive care unit with new neurologic symptoms. A neuroradiologist reviewed all radiologic images and
compared computed tomography (CT) versus magnetic resonance imaging (MRI) ﬁndings indicative of
diagnosis of PRES. Alternative imaging diagnoses explaining the patients’ symptoms were also recorded.
Fifty-four transplant recipients were admitted to the intensive care unit with new neurologic symptoms.
Thirty-nine percent (21 of 54) of subjects had imaging ﬁndings consistent with PRES, 24% (13 of 54) had
imaging ﬁndings consistent with an alternative diagnosis, 9% (5 of 54) had a nonspeciﬁc ﬁnding, and 28% (15
of 54) had no acute imaging ﬁndings. PRES was diagnosed at a median of 49 days (interquartile range, 29 to
94) after HSCT. The presenting symptom for the majority of patients with PRES was seizures (86%), whereas
14% presented with acute encephalopathy. Ninety-ﬁve percent of subjects diagnosed with PRES (20 of 21)
underwent a head CT as their initial imaging evaluation. CT scan was diagnostic of PRES in 40% (8 of 20).
Subsequently, 16 patients underwent brain MRI with 12 additional patients being diagnosed with PRES on
MRI. The median time elapsed between negative CT and a positive MRI examination was 20 hours (range,
3.6 hours to 9 days). CT serves as an excellent screening test for acute pathology, such as intracranial hem-
orrhage; however, it lacks sensitivity for the diagnosis of PRES. Patients with clinical symptoms suggestive of
PRES who have a negative CT should be treated appropriately for PRES and should undergo MRI of the brain
as soon as clinically stable to conﬁrm the diagnosis.
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ty for Blood and Marrow Transplantation.malignant and nonmalignant diseases [1]. Central nervous
system complications, however, continue to be an important
cause of morbidity and mortality in patients undergoing
transplantation [2,3]. Posterior reversible encephalopathy
syndrome (PRES) is a clinical and radiologic syndrome
characterized by vision changes, acute encephalopathy,
nausea and vomiting, focal neurologic deﬁcits, and seizures
[4]. PRES has been reported after HSCT in association with
hypertension and renal dysfunction, particularly in patients
receiving calcineurin inhibitors and corticosteroids [5-7].
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ilepsy and coma may persist [8,9].
In addition to PRES, other pathologies may lead to
neurologic symptoms after HSCT, including infection, pri-
mary disease recurrence, hemorrhage, ischemia, and post-
transplantation lymphoproliferative disease (PTLD) [10].
The majority of physicians choose computed tomography
(CT) as the initial imaging evaluation for patients who pre-
sent with neurologic symptoms because of its wide avail-
ability, timeliness, and lack of need for sedation in younger
children. The CT and magnetic resonance imaging (MRI)
manifestations of PRES have been well described in a variety
of disease backgrounds [8,11-20]. However, the diagnostic
utility of CT compared with that of MRI for PRES has not been
studied in adults or children.MATERIALS AND METHODS
HSCT recipients who underwent transplantation from January 2004
through December 2013 requiring intensive care unit admission for acute
changes in neurologic status, including seizures, encephalopathy, and visual
disturbances, and who underwent neuroimaging evaluation (CT/MRI) were
included in the study. After institutional review board approval, patients
were identiﬁed using the stem cell transplant database followed by a query
of the electronic imaging record and imaging report (Softek Illuminate;
Softek Solutions, Prairie Village, KS) databases to determine whether neu-
roimaging was performed. Demographic and transplantation data collected
included age, gender, diagnosis, stem cell source, HSCT conditioning
regimen, diagnosis of graft-versus-host disease (GVHD) at the time of PRES,
and clinical stage of GVHD at day þ100. Additionally, symptoms at the time
of PRES diagnosis were reviewed.
An attending pediatric neuroradiologist reviewed the radiology reports
and neuroimaging. Based on the imaging ﬁndings, patients were classiﬁed
into 1 of 4 categories: (1) imaging ﬁndings consistent with PRES, (2) alter-
native acute diagnosis, (3) nonspeciﬁc imaging ﬁndings possibly repre-
senting PRES with considerable possibility of alternative etiologies to
explain the imaging ﬁndings, and (4) no acute imaging ﬁndings or normal
study. The speciﬁc alternative acute diagnoses were tabulated.Diagnostic Criteria for PRES
For CT/MRI study to be diagnostic for PRES, patients had to fulﬁll 1 of 2
imaging criteria: criterion 1, cortical/subcortical signal abnormalities pre-
dominantly located in locations reported in the literature as typical for PRESFigure 1. Diagnostic imaging category of the 54 patients who underwent neuroimagin
of presentation to the pediatric intensive care unit. Category 1 PRES was diagnosed in
CT alone; 4 were diagnosed with CT and MRI; and 12 patients had normal CT, but posit
all 13 underwent CT and MRI. In category 3, 5 patients had nonspeciﬁc ﬁndings on neu
neuroimaging ﬁndings; CT was performed in all 15 patients, 5 received both CT and(between arterial territories) with relative symmetric involvement of both
cerebral hemispheres [8] or criterion 2, signal abnormalities in atypical loca-
tions (brainstem/cerebellum), as previously reported in the literature with
subsequent resolution of imagingﬁndings followingPRES-speciﬁc therapy [8].
Neuroimaging Review
Neuroimaging for all patients was reviewed and a determination of
whether ﬁndings of PRES or alternative diagnoses were present wasmade. A
CT/MRI was considered negative when both the radiology report and review
of images by the pediatric neuroradiologist were considered negative. All CT
imaging was performed without contrast. Images were reconstructed at
5 mm axial contiguous slices. No multiplanar reconstructions (coronal and
sagittal planes) were performed. The CT images were reviewed indepen-
dently of the subsequent MRI, if available. For those patients with a negative
CT and positive MRI, the number of hours between the initial CT and the
follow-up MRI examinations were recorded. Additional imaging informa-
tion for all category 1 patients was tabulated, including regions of brain
involved, associated hemorrhage and enhancement, or diffusion restriction
(when applicable imaging sequences were available for review). All brain
MRI included ﬂuid-attenuated inversion recovery, which has been shown to
bemost sensitive for detecting PRES [11]. Contrast administration, diffusion-
weighted imaging, and hemorrhage-sensitive imaging were performed
variably and are reported in the results section.
RESULTS
Eight hundred thirty-eight patients underwent HSCTover
this period. Sixty patients were admitted to the intensive
care unit with neurologic symptoms and 54 (6.4%) patients
underwent brain imaging at time of presentation (Figure 1).
Thirty-nine percent (21 of 54) of patients had imaging ﬁnd-
ings consistent with PRES (category 1). Demographic data for
these patients are presented in Table 1. PRES was diagnosed
at a median of 49 days (interquartile range, 29 to 94) after
transplantation; presenting symptoms were seizures (86%)
and acute encephalopathy (14%). The median age at HSCT
was 9.6 years (interquartile range, 5.5 to 12.6) with a ma-
jority (62%) being male. Eight patients had a marrow failure
syndrome (38%), 7 of which underwent HSCT for Fanconi
anemia. Seven patients had an immune deﬁciency (33%) and
5 patients had an underlying malignancy (24%). All 21 pa-
tients who developed PRES underwent allogeneic trans-
plantation and the majority (86%) received grafts from ang for new neurologic symptoms. All patients underwent neuroimaging at time
21 patients. One patient was diagnosed with MRI alone; 4 were diagnosed with
ive MRI. In category 2, 13 patients had an alternative diagnosis other than PRES;
roimaging; all 5 underwent CT and MRI. In category 4, 15 patients had no acute
MRI.
Table 1
Demographics of Patients Diagnosed with PRES (n ¼ 21)
Total Patients Value
Gender
Male 13 (62%)
Age at HSCT, median (interquartile Range) 9.6 yr (5.5-12.6)
Diagnosis
Malignancy 5 (24%)
Immune deﬁciency 7 (33%)
Bone marrow failure 8 (38%)
Benign hematology 1 (5%)
Stem cell source
Bone marrow 12 (57%)
Peripheral blood 4 (19%)
Cord blood 5 (24%)
Donor source
Related 3 (14%)
Unrelated 18 (86%)
Autologous 0
HLA match status
Fully matched 13 (62%)
Mismatched 8 (38%)
Conditioning regimen
Ablative 11 (52%)
Reduced intensity 10 (48%)
GVHD at time of PRES diagnosis (grade 1-4) 9 (43%)
Grade 2-4 GVHD at þ100 days 9 (43%)
Symptoms at time of PRES diagnosis
Seizures 18 (86%)
Mental status change 3 (14%)
Data presented are n (%), unless otherwise indicated.
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GVHD before the diagnosis of PRES, and 9 patients (43%) had
grade II to IV GVHD before day 100. The overall mortality in
patients who developed PRES was 62% (8 of 21 survived). Ten
patients died from GVHD, 2 from disseminated fungal
infection, and 1 from disease relapse.
Speciﬁc ﬁndings, such as hypertension and thrombotic
microangiopathy, are only available on patients who devel-
oped PRES after 2010. We were able to obtain blood pressure
data on 11 of the 21 patients diagnosed with PRES (52%). All
11 patients had refractory hypertension, requiring at least 2
antihypertensive medications in the 24 hours before the
onset of symptoms, 8 of the 11 (73%) were being treated with
calcineurin inhibitors, and 9 of the 11 (82%) met diagnostic
criteria for thrombotic microangiopathy.Figure 2. Four-year-old female with severe combined immune deﬁciency who develo
attenuation and loss of the gray-white junction in a nonvascular, watershed distribuAll but 1 patient (20 of 21, 95%) diagnosed with PRES had
a head CT scan done as a ﬁrst imaging study, with 40% (8 of
20) of patients having CT ﬁndings diagnostic of PRES
(Figure 2). MRI was performed in 16 of these 21 patients
(76%) and all studies were consistent with PRES, including
12 patients with negative CT ﬁndings during initial evalu-
ation (Figure 3). The median time between negative CT
examination and a positive MRI examination was 20 hours
(range, 3.6 hours to 9 days). Diffusion-weighted imaging
was performed in all 16 patients with diagnosis of PRES who
underwent MRI. Areas of diffusion restriction were identi-
ﬁed in 4 of the 16 patients. Intravenous contrast was
administered in 8 of the patients receiving MRI, 1 of which
showed abnormal contrast enhancement. Hemorrhage-
sensitive MRI sequences (susceptibility-weighted imaging
or gradient echo) were performed in 11 of the 16 patients, 3
of which demonstrated intraparenchymal hemorrhage in
the regions of signal abnormality. Hemorrhage was identi-
ﬁed on CT in 2 of these 3 patients. Brain regions affected in
the 22 subjects diagnosed with PRES were as follows:
frontal (14 of 21, 66%), parietal-occipital (19 of 21, 90%),
temporal (8 of 21, 38%), cerebellum (3 of 21, 14%), and
brainstem (2 of 21, 10%). Ten of the 21 patients (48%) had
follow-up neuroimaging: all showed complete or near-
complete resolution.
One quarter of patients (24%, 13 of 54) in this cohort had
neuroimaging suggestive of an alternative diagnosis (cate-
gory 2) including intracranial hemorrhage (3 patients), hy-
drocephalus (2 patients), metastatic disease (2 patients),
acute infarction (2 patients), nonalcoholic Wernicke en-
cephalopathy (1 subject), orbital abscess (1 subject), PTLD (1
subject), and nonspeciﬁc basal ganglia/thalamic lesions (1
subject). Eight of the 13 patients (62%) with acute alternative
diagnoses had ﬁndings evident on CT, including intracranial
hemorrhage, hydrocephalus, PTLD, infarction, and orbital
abscess. Five patients (38%) with acute alternative diagnoses
had imaging ﬁndings only seen on MRI, including metastatic
disease, infarction, nonalcoholic Wernicke encephalopathy,
and nonspeciﬁc basal ganglia/thalamic lesions. Five (9%, 5 of
54) had new nonspeciﬁc imaging ﬁndings (category 3). The
remainder of patients (28%, 15 of 54) had normal or no acute
imaging ﬁndings (category 4). Of these patients, 10 had CT
only, and it is unknown if additionalMRI imagingwould have
identiﬁed PRES.ped seizures 5 days after HSCT. Axial CT images show large areas of decreased
tion, most consistent with PRES. No MRI was performed.
Figure 3. Seven-year-old male who developed seizures 68 days after HSCT. (A) Head CT examination was normal. (B) Axial ﬂuid-attenuated inversion recovery
images from a brain MRI examination performed 4 hours later demonstrates multiple cortical and subcortical foci of signal abnormality consistent with PRES.
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CT is a good ﬁrst test in HSCT patients with acute
neurologic changes when intracranial hemorrhage, space
occupying lesions, and hydrocephalus need to be ruled out
quickly. However, our ﬁndings suggest that CT lacks sensi-
tivity for diagnosis of PRES. Only 40% of patients diagnosed
with PRES on MRI had radiologic evidence of PRES on CT.
Our study validates others’ ﬁndings and suggests that MRI
may be more sensitive to detect microhemorrhage within
the affected areas of the brain [21,22]. Despite a negativeFigure 4. Diagnostic algorithm for patients with new neuinitial head CT, if clinical symptoms are suggestive of PRES,
HSCT patients should receive prompt and aggressive hyper-
tension management and anticonvulsant therapy, and a
diagnostic MRI should be obtained when clinically feasible.
Limitations of this study include 10 of the 15 patients
with no acute imaging ﬁndings (category 4) who underwent
CT imaging only. It is possible that additional acute di-
agnoses would have been revealed if follow-up MRI had
been performed in these patients. This retrospective study is
a nonuniform evaluation of subjects with neurologicrologic symptoms after stem cell transplantation.
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including PRES, was missed. Additionally, the time between
CT and MRI examinations was variable, allowing the possi-
bility that some ﬁndings of PRES evolved in between the CT
and MR examinations. However, a number of false-negative
CT examinations performed only a few hours before the
positive MRI examinations support our observation that
MRI is the preferred study for diagnosis of PRES (eg,
Figure 3). MRI can identify subtle cortical/subcortical signal
abnormalities characteristic of PRES better than CT. Finally,
at the time of this study, CT examinations were routinely
reconstructed only in the axial plane. At our institution, it is
now standard of care to reconstruct head CT examinations
in the sagittal and coronal planes, which may increase the
sensitivity and accuracy of this examination for detection of
PRES.
We propose that patients with acute neurologic symp-
toms after HSCT in the setting of hypertension or throm-
botic microangiopathy receive aggressive hypertension
management [23]. Patients with neurologic changes should
receive an MRI if rapidly available; otherwise, a CT scan
should be obtained to evaluate for acute pathology. If PRES
is suspected despite a negative CT scan, or if PRES is found
on CT, PRES-speciﬁc therapy should be initiated, including
aggressive hypertension management and anticonvulsant
therapy. MRI should be obtained when clinically stable
(Figure 4).
In summary, CT examinations are a good initial diag-
nostic test for HSCT patients presenting with acute mental
status changes or seizures. CT often identiﬁes an alternative
diagnosis or can make a deﬁnitive diagnosis of PRES.
However, our ﬁndings demonstrate that CT is insensitive
compared with MRI for PRES. Patients with negative CT
ﬁndings but clinical symptoms highly suggestive of PRES
should undergo an MRI of the brain when clinically stable
and receive aggressive hypertension control. MRI results
diagnostic of PRES or alternative diagnoses may prompt
physicians to make appropriate management changes
regarding hypertension control, aid in decision-making
regarding invasive diagnostic procedures (including lum-
bar puncture), and/or intensify ongoing empiric antimicro-
bial/antifungal therapy.ACKNOWLEDGMENTS
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